0000000000564010

AUTHOR

Miquel Navasa

showing 2 related works from this author

Hepatitis C virus intrinsic molecular determinants may contribute to the development of cholestatic hepatitis after liver transplantation

2018

Cholestatic hepatitis C (CHC) is a severe form of hepatitis C virus (HCV) infection recurrence that leads to high graft loss rates early after liver transplantation (LT). To investigate the pathogenic mechanisms of CHC, we analysed HCV quasispecies in CHC patients compared to a control group (mild hepatitis C recurrence) by deep pyrosequencing. At the time of LT, NS5B quasispecies complexity was similar between the two groups but, after LT, it decreased more sharply in CHC patients than in the control group. Interestingly, the major variant before LT propagated efficiently and remained as the dominant sequence after LT in 62 % of CHC patients versus 11 % of controls (P=0.031). Sequence anal…

0301 basic medicineMalemedicine.medical_specialtyGenotypeDeep sequencingSequence analysismedicine.medical_treatmentHepatitis C virus030106 microbiologyViral quasispeciesHepacivirusLiver transplantationBiologyViral Nonstructural ProteinsGraft lossmedicine.disease_causeGastroenterology03 medical and health scienceschemistry.chemical_compoundVirologyInternal medicinemedicineHumansNS5BAgedLiver transplantationHepatitis C virusHigh-Throughput Nucleotide SequencingHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseVirologyCholestatic hepatitis CLiver TransplantationJaundice ObstructiveQuasispecies030104 developmental biologychemistryCholestatic hepatitisFemale
researchProduct

HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans.

2014

Pathogen-induced immune responses prevent the establishment of transplantation tolerance in experimental animal models. Whether this occurs in humans as well remains unclear. The development of operational tolerance in liver transplant recipients with chronic hepatitis C virus (HCV) infection allows us to address this question. We conducted a clinical trial of immunosuppression withdrawal in HCV-infected adult liver recipients to elucidate (i) the mechanisms through which allograft tolerance can be established in the presence of an ongoing inflammatory response and (ii) whether anti-HCV heterologous immune responses influence this phenomenon. Of 34 enrolled liver recipients, drug withdrawal…

Graft RejectionMaleHepatitis C virusT cellmedicine.medical_treatmentHepacivirusLiver transplantationCD8-Positive T-Lymphocytesmedicine.disease_causeImmune systemInterferonmedicineImmune ToleranceHumansLymphocyte CountImmunosuppression Therapybusiness.industryImmunityImmunosuppressionReceptors Antigen T-Cell gamma-deltaGeneral MedicineMiddle Agedmedicine.diseaseLiver TransplantationTransplantationmedicine.anatomical_structureGene Expression RegulationImmunologyInterferon Type IFemaleViral hepatitisbusinessBiomarkersmedicine.drugScience translational medicine
researchProduct